Compare Roundhill Magnificent Seven ETF (MAGS) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Magnificent Seven ETF vs Medpace Holdings Inc — how do they compare? Roundhill Magnificent Seven ETF trades at $73.69 (market cap $5.78B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 2.9× Roundhill Magnificent Seven ETF's market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 4,410,665). Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Magnificent Seven ETF for 36 Days and Medpace Holdings Inc for 14 Days on average.
| MAGS | MEDP | |
|---|---|---|
Market Cap | $5.78B | $16.82B |
Volume | 4,410,665 | 223,093 |
Sector | Sector/Thematic | Health |
52-Week High | $73.90 | $630.19 |
52-Week Low | $55.39 | $393.42 |
Typical Hold Time | 36 Days | 14 Days |
Enterprise Value | — | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAGS trades at $73.66, showing minimal daily movement with a slight 0.04% decline. Technical indicators signal a bullish trend with strong moving average support, while oscillators remain neutral. The ETF provides equal-weighted exposure to the Magnificent Seven mega-cap tech stocks, though recent performance has trailed broader market indexes with modest 2% year-to-date gains.
The outlook remains cautiously optimistic given the ETF's concentrated tech exposure and AI growth themes. Key risks include market concentration, valuation concerns, and potential regulatory scrutiny. Wall Street sentiment appears mixed as investors weigh long-term AI potential against near-term performance challenges.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
